Del, DRD2 rs1800497, DRD4 VNTR, COMT rs4680 & SLC6A3 VNTR) dopamine pathway genetic risk score predicted 10.9% of the inter-individual variation in ventral striatum reactivity – a probable site of action for bupropion(25), which was greater than the contribution of any single variant alone (26) and Stice and colleagues also reported that a multilocus dopamine score using the same variants but a different scoring and weighting scheme was associated with brain reward circuitry reactivity (27).
